Q3 Net Loss Widens to $3.3M as Cash Falls to $9.1M; Runway Into Q2 2027
REVB sits 16% above its 52-week low of $3.08.
Summary
Revelation's third-quarter net loss widened to $3.3 million from $1.9 million a year earlier, with Q3 EPS of -5.92, and the nine-month loss reached $9.6 million versus $6.4 million. Cash fell to $9.1 million at September 30 from $10.7 million at year-end 2025, and management says that funds operations only into the second quarter of 2027. Operating cash burn accelerated to $2.6 million in the quarter from $1.6 million a year ago, with R&D spending up to $4.8 million for nine months from $3.1 million. The release also notes a $94 billion total addressable market assessment for Gemini and the selection of a global CRO for the upcoming acute kidney injury study. This follows the 10-Q filed minutes earlier and comes two weeks after the 1-for-7 reverse split took effect on October 20, 2026. The company is a clinical-stage story with no revenue, so the runway into Q2 2027 is the number that matters — any AKI study start will need cash before then.
At the time of this announcement, REVB was trading at $3.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2M. The 52-week trading range was $3.08 to $40.60. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: BusinessWire.